Lucrin Depot Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Leuprorelin acetate

Indications/Uses

Palliative treatment of advanced prostatic cancer. 3.75 & 11.25 mg depot for inj: Treatment of endometriosis for a period of 6 mth as monotherapy or adjunct to surgery. Pre-op treatment for leiomyoma uteri for a period of 6 mth. Breast cancer in pre- & peri-menopausal women in which hormone therapy is specified. 3.75 mg depot for inj: Childn w/ central precocious puberty.

Dosage/Direction for Use

3.75 mg depot for inj Prostate & breast cancer, endometriosis, endometriosis w/ add-back, uterine fibroids Administer 3.75 mg mthly as a single IM/SC inj. Central precocious puberty Individualized dosage. Initially 0.3 mg/kg/4 wk SC/IM inj. 11.25 mg depot for inj Administer 11.25 mg as a single SC/IM inj every 3 mth. 30 mg depot for inj Administer 30 mg as single SC inj every 6 mth.

Contraindications

Hypersensitivity to leuprorelin acetate or similar nonapeptides. Undiagnosed vag bleeding. Women who are or may become pregnant during treatment. Pregnancy & lactation.

MIMS Class

Cancer Hormone Therapy / Trophic Hormones & Related Synthetic Drugs

ATC Classification

L02AE02 - leuprorelin ; Belongs to the class of gonadotropin releasing hormone analogues. Used in endocrine therapy.

Regulatory Classification

POM

Presentation/Packing

Form

Lucrin Depot powd for soln for inj 11.25 mg

Packing/Price

1's

Form

Lucrin Depot powd for soln for inj 3.75 mg

Packing/Price

1's

Form

Lucrin Depot powd for soln for inj 30 mg

Packing/Price

1's

Lucrin Depot

leuprorelin

Manufacturer:

Takeda